Affiliation:
1. National Cancer Center/ National Clinical Reasearch Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
2. National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
3. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College
Abstract
Abstract
Purpose
This study compares image features influencing false-positive lesions in category 4a between handheld ultrasound (HHUS) and automated breast ultrasound (ABUS) and explores the role of second-look mammography (MAM) adjunct to US of 4a masses.
Methods
Women aged 30 to 69 underwent HHUS and ABUS from 2016 through 2017 at five high-level hospitals in China with those aged 40 or older also accepting MAM. Logistic regression analysis assessed image variables correlated with false-positive lesions in US category 4a. Unnecessary biopsies, invasive cancer (IC) yields, and diagnostic performance among different biopsy thresholds were compared.
Results
1946 women (44.9±9.8 years) were eligible for analysis. 188 (9.66%) were categorized as category 4a in HHUS and 117 (6.01%) of ABUS. Orientation, architectural distortion, and duct change were independent factors associated with the false-positive lesions in 4a of HHUS, whereas premenopausal, size, calcification, and architectural distortion were significant features of ABUS (all P<0.05). For HHUS, both unnecessary biopsy rate and IC yields were significantly reduced when changing biopsy thresholds by adding MAM for US 4a patients (scenario #1:BI-RADS 3, 4, and 5; scenario #2: BI-RADS 4 and 5) compared with the current scenario (all P<0.05). However, scenario #1 reduced false-positive biopsies without affecting IC yields when compared to the current scenario for ABUS (P<0.001; P=0.125).
Conclusions
The higher unnecessary biopsy rate of category 4a by ABUS was similar to HHUS. However, the second-look MAM adjunct to ABUS has the potential to safely reduce false-positive biopsies.
Publisher
Research Square Platform LLC